Non Invasive Options Stay Popular for Basal Cell Carcinoma Treatments
Basal cell carcinoma is one of the most common types of skin cancers observed around the world. Conventionally, the disease has been treated with procedures such as standard surgical excisions, and curettage. The risk of contracting the disease increases among people who have immunosuppression issues, fair skin, genetic disorders, exposure to ultraviolet light, and a history of BCC.
The global basal cell carcinoma treatment market is projected to grow at an impressive CAGR of 9 per cent through the forecast period till 2025. This growth can be attributed to the increased investments being made by healthcare and pharmaceutical industries into the development of better drug formulations, with the aim of cutting down the risk of basal cell carcinoma.
Increased Use of Contract Research Organizations and Radiotherapy Gain Traction
Countries in the Asia Pacific and North America regions are expected to display a high potential for growth for the basal cell carcinoma treatment market, which can be attributed to the rising patient awareness about the ailment and the recent advancements and growing range of treatment options including Mohs micrographic surgery, superficial field therapies, and electrodessication.
Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=4366
In addition, a number of contract research organizations such as the Skin Cancer Foundation have come up, which have been pushing to increase awareness about the cancer, while also creating training programs for health care professionals for the correct implementation of new treatment options.
Further, countries in the Asia Pacific region are expected to generate substantial revenue generation opportunities, in comparison numerous regions in such treatment markets on a global scale. Contract research organizations are also providing new information and insight on treatments such as radiotherapy, which is substantially influencing the landscape of the market.
Non-invasive Treatments are Major Contributors
While surgical treatments have been the most popular conventionally, patients are increasingly preferring to opt for non-invasive treatments such as superficial radiation therapy (SRT) as such treatment results in lesser risk of complications.
Read Report Overview- https://www.factmr.com/report/4366/basal-cell-carcinoma-treatment-market
In addition, delays in treating basal cell carcinoma can result in issues with bone, skin, and muscle damage, which has also contributed to the increased adoption of SRT over the increasingly impractical practice of radiotherapy.
In addition, the older conventional methods and machines of SRT has become obsolete, and create challenges in terms of operations and maintenance. Consequently, modernization of these equipment is working as a catalyst to the growth of the global basal cell carcinoma market.
SRT has been found to result in better outcomes for the patients, as treatments can only impact cancer cells, leaving healthy cells unaffected. Consequently, the rate of adoption has also gone up in terms of specialty clinics and hospitals. In addition, such equipment also finds roles in treating squamous cell carcinoma as well, increasing demand.
Drugs are also another popular treatment option, owing to the recent introduction of hedgehog pathway inhibitors, which will witness substantial growth in this period. On the other hand, side effects such as resistance to drugs, and muscle spasms are expected to restrict growth to an extent.
Request Research Methodology- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4366
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852